Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Bristol-Myers: Onglyza Achieves Primary Safety Endpoint - Quick Facts

AstraZeneca Plc. (AZN: Quote,AZN.L) and Bristol-Myers Squibb Co. (BMY: Quote) announced the full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular events. In this study, Onglyza or saxagliptin met the primary safety objective, demonstrating no increased risk for the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction or MI or non-fatal ischemic stroke, when added to a patient's current standard of care (with or without other anti-diabetic therapies), as compared to placebo.

The company said that Onglyza did not meet the primary efficacy endpoint of superiority to placebo for the same composite endpoint. Patients treated with Onglyza experienced improved glycemic control and reduced development and progression of microalbuminuria over two years as assessed in exploratory analyses. According to the company, the major secondary composite endpoint of cardiovascular death, non-fatal MI, non-fatal ischemic stroke or hospitalization for heart failure, unstable angina or coronary revascularization was balanced across the two arms. One component of the composite secondary endpoint, hospitalization for heart failure, occurred more in the Onglyza group compared to placebo. Rates of pancreatitis were low and balanced between Onglyza and placebo. Overall rates of malignancy were balanced, and the observed rates of pancreatic cancer were lower in the Onglyza group than in the placebo group. More patients in the Onglyza group reported at least one hypoglycemic event compared to placebo.

As of September 2013, Onglyza is approved in 86 countries including those in the European Union, the United States, Canada, Mexico, India, Brazil and China.

Register
To receive FREE breaking news email alerts for AstraZeneca PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ireland's economy grew for the second consecutive quarter in the three months to June, latest figures from the Central Statistics Office showed Thursday. Gross domestic product grew a seasonally adjusted 1.5 percent sequentially following 2.8 percent expansion in the first quarter, revised from 2.7... A historic referendum that decides the future of Scotland has begun. The Scots are voting Thursday on whether Scotland should become an independent country or stay in the United Kingdom. Voting opened at 7am local time in more than 2,600 polling stations, where voters are given the "Yes" and "No" options to the referendum question: "Should Scotland be an independent country?." More than four milli The European Central Bank announced Thursday the results of its first targeted longer term refinancing operation, or TLTRO, which is aimed to boost liquidity at Eurozone banks to help revive lending to small businesses and households. The central bank announced that 255 bidders were allotted EUR 82.60...
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.